🚀 VC round data is live in beta, check it out!
Nuvation Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nuvation Bio and similar public comparables like Phibro Animal Health, Harrow, Soleno Therapeutics, Cheezheng Tibetan Medicine and more.
Nuvation Bio Overview
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Founded
2020
HQ
Employees
220
Website
Sectors
Financials (LTM)
EV
$2B
Nuvation Bio Financials
Nuvation Bio reported last 12-month revenue of $90M and negative EBITDA of ($205M).
In the same LTM period, Nuvation Bio generated $78M in gross profit, ($205M) in EBITDA losses, and had net loss of ($195M).
Revenue (LTM)
Nuvation Bio P&L
In the most recent fiscal year, Nuvation Bio reported revenue of $63M and EBITDA of ($189M).
Nuvation Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $90M | XXX | $63M | XXX | XXX | XXX |
| Gross Profit | $78M | XXX | $54M | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | ($205M) | XXX | ($189M) | XXX | XXX | XXX |
| EBITDA Margin | (227%) | XXX | (301%) | XXX | XXX | XXX |
| EBIT Margin | (221%) | XXX | (339%) | XXX | XXX | XXX |
| Net Profit | ($195M) | XXX | ($205M) | XXX | XXX | XXX |
| Net Margin | (216%) | XXX | (325%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nuvation Bio Stock Performance
Nuvation Bio has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Nuvation Bio's stock price is $5.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-0.60 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNuvation Bio Valuation Multiples
Nuvation Bio trades at 17.0x EV/Revenue multiple, and (7.5x) EV/EBITDA.
EV / Revenue (LTM)
Nuvation Bio Financial Valuation Multiples
As of March 21, 2026, Nuvation Bio has market cap of $2B and EV of $2B.
Equity research analysts estimate Nuvation Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nuvation Bio has a P/E ratio of (10.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 17.0x | XXX | 24.4x | XXX | XXX | XXX |
| EV/EBITDA | (7.5x) | XXX | (8.1x) | XXX | XXX | XXX |
| EV/EBIT | (7.7x) | XXX | (7.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 19.6x | XXX | 28.6x | XXX | XXX | XXX |
| P/E | (10.4x) | XXX | (9.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nuvation Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nuvation Bio Margins & Growth Rates
Nuvation Bio's revenue in the last 12 month grew by 135%.
Nuvation Bio's revenue per employee in the last FY averaged $0.4M.
Nuvation Bio's rule of 40 is (92%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nuvation Bio's rule of X is 110% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Nuvation Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 135% | XXX | 201% | XXX | XXX | XXX |
| EBITDA Margin | (227%) | XXX | (301%) | XXX | XXX | XXX |
| EBITDA Growth | (25%) | XXX | (3%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (92%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 110% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 162% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 134% | XXX | 183% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 424% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nuvation Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Phibro Animal Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Harrow | XXX | XXX | XXX | XXX | XXX | XXX |
| Soleno Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cheezheng Tibetan Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Aurinia Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nuvation Bio M&A Activity
Nuvation Bio acquired XXX companies to date.
Last acquisition by Nuvation Bio was on XXXXXXXX, XXXXX. Nuvation Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nuvation Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNuvation Bio Investment Activity
Nuvation Bio invested in XXX companies to date.
Nuvation Bio made its latest investment on XXXXXXXX, XXXXX. Nuvation Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nuvation Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nuvation Bio
| When was Nuvation Bio founded? | Nuvation Bio was founded in 2020. |
| Where is Nuvation Bio headquartered? | Nuvation Bio is headquartered in United States. |
| How many employees does Nuvation Bio have? | As of today, Nuvation Bio has over 220 employees. |
| Who is the CEO of Nuvation Bio? | Nuvation Bio's CEO is David T. Hung. |
| Is Nuvation Bio publicly listed? | Yes, Nuvation Bio is a public company listed on NYSE. |
| What is the stock symbol of Nuvation Bio? | Nuvation Bio trades under NUVB ticker. |
| When did Nuvation Bio go public? | Nuvation Bio went public in 2021. |
| Who are competitors of Nuvation Bio? | Nuvation Bio main competitors are Phibro Animal Health, Harrow, Soleno Therapeutics, Cheezheng Tibetan Medicine. |
| What is the current market cap of Nuvation Bio? | Nuvation Bio's current market cap is $2B. |
| What is the current revenue of Nuvation Bio? | Nuvation Bio's last 12 months revenue is $90M. |
| What is the current revenue growth of Nuvation Bio? | Nuvation Bio revenue growth (NTM/LTM) is 135%. |
| What is the current EV/Revenue multiple of Nuvation Bio? | Current revenue multiple of Nuvation Bio is 17.0x. |
| Is Nuvation Bio profitable? | No, Nuvation Bio is not profitable. |
| What is the current EBITDA of Nuvation Bio? | Nuvation Bio has negative EBITDA and is not profitable. |
| What is Nuvation Bio's EBITDA margin? | Nuvation Bio's last 12 months EBITDA margin is (227%). |
| What is the current EV/EBITDA multiple of Nuvation Bio? | Current EBITDA multiple of Nuvation Bio is (7.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.